Creating cells that produce a protective protein to treat osteoarthritis
In situ Cell Engineering for On-demand TIMP Expression in Osteoarthritis
This study is testing a new way to help people with osteoarthritis by using special cells that can make a protein to protect their joints, aiming to slow down damage and inflammation so they can feel better and possibly avoid surgery in the future.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-10451707 on NIH RePORTER |
What this research studies
This research focuses on developing a novel approach to treat osteoarthritis (OA) by engineering cells in the body to produce a protein called TIMP-3 that can help protect joints. The method involves using a non-viral CRISPR-based nanoparticle to insert a gene into cells, allowing them to produce TIMP-3 only when OA-related damage occurs. This targeted approach aims to reduce cartilage degradation and inflammation, potentially offering a long-term solution for patients suffering from OA. By addressing the disease at an earlier stage, the research seeks to improve patient outcomes and reduce the need for joint replacement surgeries.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals over 40 years old who are experiencing symptoms of osteoarthritis or have a history of joint injuries leading to post-traumatic osteoarthritis.
Not a fit: Patients with advanced osteoarthritis requiring immediate surgical intervention or those who do not have OA-related symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a disease-modifying treatment for osteoarthritis, significantly improving joint health and quality of life for patients.
How similar studies have performed: While the approach of using gene therapy for osteoarthritis is relatively novel, similar strategies in other conditions have shown promise, indicating potential for success in this area.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Duvall, Craig Lewis — Vanderbilt University
- Study coordinator: Duvall, Craig Lewis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.